about
Eating disorders in schizophrenia: implications for research and managementPharmacological interventions for reducing weight gain in schizophreniaPharmacological mechanisms underlying the association of antipsychotics with metabolic disordersInflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical ImplicationsPreventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatmentMetabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general populationPrevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum DisordersAre antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment.Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables.Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials.Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study.Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Clinical predictors of therapeutic response to antipsychotics in schizophreniaEtiologies of obesity in children: nature and nurture.Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychoticsRisperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure.Safety and tolerability of antipsychotic polypharmacy.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study.Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.2-Bromoterguride-a potential atypical antipsychotic drug without metabolic effects in rats.Perspectives on medicine adherence in service users and carers with experience of legally sanctioned detention and medication: a qualitative studyAssociations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods.Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis.Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese.Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics.Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.Emerging drugs for schizophrenia: an update.Do antipsychotics increase diabetes risk in children and adolescents?Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management.Proteome effects of antipsychotic drugs: Learning from preclinical models.
P2860
Q21284525-828FD67A-A25F-4B16-99C3-06A2F14C55AEQ24194410-B97F5FE2-CC0F-4AB7-BF22-7042AD3857D2Q26999668-4688E5AC-5B61-4810-88B6-3BD3A02EEDEAQ28066646-5763EEFC-5729-4BCA-AF61-ECECB3E461DBQ28541531-C483242D-F4CB-4741-BAEF-78C0E8D984E4Q33622056-67C6643B-9E47-4902-8DC6-F18839DD0713Q33670588-41EAFFD2-9658-4C53-A049-7614156B4A49Q33802927-CCBDCC8B-303C-4D9F-B3D7-995685CD751EQ34266656-29853EAD-E1B1-4726-BEB1-7ADDF53EFB00Q34386877-5A06AC3D-5D9D-4D47-8716-7C4A57A36D39Q34641561-809E2913-1F73-46EA-8334-6CB4D2DFBA24Q34680043-9AD7F28F-3996-48EE-9FA7-C4D5224C0B1DQ35087495-0BC17526-CF65-4143-99E6-CE9071FAC621Q35088447-863B1040-F5CA-450D-83C4-B028534889ECQ35109168-D0CB1EA5-72B2-4600-B9DF-0016F8D7B612Q35575493-0DBD76DF-22F5-4632-8F0E-5C54D44B35A0Q35873789-109AF1E5-68A4-4D37-B59B-CC4613559CA8Q35921844-00F368D1-88BE-40A7-8D6D-B03166562885Q36062421-84141E0B-9F5A-4057-BA8E-23068DAE77D1Q36063735-42CA5F25-D873-42A2-83CD-0603B48A0B9EQ36075717-724BEFAE-D5CB-4E83-BCF8-4FC79588C7F4Q36966228-7E2A42E4-CE4F-4492-827C-81B5E6332EAEQ37061277-FB14ED09-9881-4650-863C-0967D8984724Q37067125-790B7B68-AB87-4E16-B01A-3D09A398D5C3Q37109707-6822942E-FDE9-44D4-BEB6-C0A1CDED8EABQ37244634-A4E7215F-AD59-4B7B-8424-FE42615E6F9CQ37354917-74741E67-B82D-483B-8D39-68E2B9C4E814Q37635208-6D503221-EA0C-4A68-B4C6-2834459A7212Q37684797-475FC6ED-161D-4BF8-8AF3-DBBF27CFB015Q37714911-18FBFBA6-2697-46D7-9ED3-0F497D8662A4Q37725043-E4D56BA2-FA47-4AF7-B669-C991859728ECQ37947095-9E6AB48F-E156-4FB3-B670-BF67B5792111Q38042478-E98F1C75-EA4E-46C8-8A29-694D941A4906Q38103807-D7BC667F-38BA-4933-B9E9-6298AF43DEB8Q38170310-3FC7E31F-3462-4F4B-AC29-F5CF5594A3F9Q38252404-42696921-E7DD-4FF2-B9AC-BDDAF83B3A2AQ38283956-5E025AFB-5B32-4ABF-A40B-3F33E377DF74Q38375731-5F1EB03C-3656-4429-8590-FF98C967BE84Q38504254-CE4AAFD8-DBB9-4632-B156-CDFA6907CA8FQ38628112-FCD7CAEF-40C5-4B9C-87F4-F28E168B9347
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Antipsychotic drugs and obesity.
@ast
Antipsychotic drugs and obesity.
@en
Antipsychotic drugs and obesity.
@nl
type
label
Antipsychotic drugs and obesity.
@ast
Antipsychotic drugs and obesity.
@en
Antipsychotic drugs and obesity.
@nl
prefLabel
Antipsychotic drugs and obesity.
@ast
Antipsychotic drugs and obesity.
@en
Antipsychotic drugs and obesity.
@nl
P2860
P1476
Antipsychotic drugs and obesity.
@en
P2093
Anil K Malhotra
Christoph U Correll
P2860
P304
P356
10.1016/J.MOLMED.2010.10.010
P50
P577
2010-12-22T00:00:00Z